UK-China AMR Collaboration Competition

Dear All: 

It is great to see that the UK Department of Health (DH) and the Chinese Ministry of Science and Technology (MoST) have today announced the size, scope and eligibility for the UK-China AMR Collaboration that was initially announced in 2016. DH will to invest up to £10 million in UK businesses and MoSt will provide to 60 million RMB to fund the Chinese partners. The competition will open at the start of 2018 — more precise dates will be announced in due course.

The aim is to support novel products or services against antimicrobial resistance (AMR) that neither country would be able to conduct within the same timeframe without the other’s expertise. Where appropriate, clinical evaluation can be supported. Specifically, the call will seek projects that:

  • explore opportunities from traditional Chinese medicine for the treatment or prevention of infectious diseases in humans or animals
  • advance the discovery of new agents to prevent or treat drug-resistant bacterial infection in humans or livestock. New agents could include small molecule drugs, vaccines, antibodies or other biological products
  • identify new agents that will increase the feed energy conversion in livestock. This should be done without use of antibiotics or hormones
  • maximise the clinical utility of current antibiotics. The aim is to improve the prognosis of patients with extensively drug-resistant infections
  • improve capabilities for the diagnosis, treatment selection and surveillance of bacterial infections and antibacterial resistance

The Knowledge Transfer Network (KTN) and Innovate UK will be hosting a number of roadshows across the UK to publicise the competition as well as activity to support partnership building with Chinese researchers.  Gabriela Juarez Martinez from the KTN (gabriela.juarezmartinez@ktn-uk.org) can provide more information to interested researchers. Projects will need to comply with Official Development Assistance (ODA) criteria.

Well done to all for working to make this happen!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog.html

Upcoming meetings of interest to the AMR community:

Share

Path to UNGA 2024 as of 3 May 24 / Events on 14-15 May (DC, NYC)

Dear All, Well, ECCMID 2024 (Barcelona) has come and gone. I saw many of you there … but it’s always so busy … and the conference center was simply enormous! Could not keep up. But, it was great to get the sense that we’re back as a community … very good attendance. The one thing

R&D Implications: Global Burden Disease is 28% Infectious!

Dear All (with thanks to Erin Duffy for co-authoring and with a wonkish alert! Refresh your coffee!), In a fascinating follow-up to their 2022 paper on the global burden of antimicrobial resistance (20 Jan 2022 newsletter entitled “#AMRSOS! GRAM Report: ‘At Least 1.27m Deaths/Year Directly Attributable To AMR’”), the team at IHME (Institute for Health

OHE £40k Policy Innovation Prize: AMR, anyone?

Dear All, One of your alert co-readers (Abigail Herron) pointed out to me the currently open call for applications for the OHE (Office of Health Economics) Innovation Policy Prize, a biennial £40k prize seeking “to promote thought leadership and solution-based theories around the big questions affecting the future of our industry.” Intriguingly for the AMR community, their

WHO call for data on pre-clinical antifungal R&D projects

Dear All, As part of their long-running project to maintain a useful view of the global antibacterial and antifungal pipelines, WHO yesterday announced a call for data on pre-clinical antifungal R&D projects. The scope is anything from Lead Optimization to pre-IND. Here are the links you need: The WHO webpage describing the call for data

Scroll to Top